Is there an association between Ro52/TRIM21 antibodies and rheumatoid factor in systemic sclerosis?

Rheumatology International

Volumn 34, Issue 3, 2014, Pages 425-427

  Mehra, Sonal ^a   Hudson, Marie ^b   Mahler, Michael ^c   Baron, Murray ^b   Fritzler, Marvin ^d  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b MCGILL UNIVERSITY   (Canada)

^c INOVA DIAGNOSTICS INC   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BINDING PROTEIN; RHEUMATOID FACTOR; RO52 PROTEIN; TRIM21 PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; DISEASE ASSOCIATION; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOASSAY; LETTER; MYOSITIS; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMIC SCLEROSIS;

ADULT; AGED; AUTOANTIBODIES; BIOLOGICAL MARKERS; CANADA; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RHEUMATOID FACTOR; RIBONUCLEOPROTEINS; SCLERODERMA, SYSTEMIC;

EID: 84896698371     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-013-2728-x     Document Type: Letter

References (10)

1. Peene I, Meheus L, De Keyser S, Humbel R, Veys EM, De Keyser F (2002) Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease. Ann Rheum Dis 61(10):929-933
2. Hudson M, Pope J, Mahler M, Tatibouet S, Steele R, Baron M, Canadian Scleroderma Research Group (CSRG), Fritzler M (2012) Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther 14(2):R50
3. Schulte-Pelkum J, Fritzler M, Mahler M (2009) Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev 8(7):632-637
4. Takahata M, Bohgaki M, Tsukiyama T, Kondo T, Asaka M, Hatakeyama S (2008) Ro52 functionally interacts with IgG1 and regulates its quality control via the ERAD system. Mol Immunol 45(7):2045-2054
5. Retamozo S, Akasbi M, Brito-Zeron P, Bosch X, Bove A, Perez-de-Lis M, Jimenez I, Soto-Cardenas MJ, Gandia M, Diaz-Lagares C, Vinas O, Siso A, Perez-Alvarez R, Yague J, Ramos-Casals M (2012) Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sjogren's syndrome. Clin Exp Rheumatol 30(5):686-692
6. Dugar M, Cox S, Limaye V, Gordon TP, Roberts-Thomson PJ (2010) Diagnostic utility of anti-Ro52 detection in systemic autoimmunity. Postgrad Med J 86(1012):79-82
7. Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Yazawa N, Tamaki K (2004) Rheumatoid factor isotypes and anti-agalactosyl IgG antibodies in systemic sclerosis. Br J Dermatol 151(4):803-808
8. Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K (2005) Clinical and laboratory features of scleroderma patients developing skeletal myopathy. Clin Rheumatol 24(2):99-102
9. Ueda-Hayakawa I, Hasegawa M, Kumada S, Tanaka C, Komura K, Hamaguchi Y, Takehara K, Fujimoto M (2010) Usefulness of anti-cyclic citrullinated peptide antibody and rheumatoid factor to detect rheumatoid arthritis in patients with systemic sclerosis. Rheumatology (Oxford) 49(11):2135-2139
10. Pakozdi A, Nihtyanova S, Moinzadeh P, Ong VH, Black CM, Denton CP (2011) Clinical and serological hallmarks of systemic sclerosis overlap syndromes. J Rheumatol 38(11):2406-2409